Deep Learning of Semi-Competing Risk Data via a New Neural Expectation-Maximization Algorithm
This work addresses prognostication challenges in lung cancer survival analysis for medical researchers and clinicians, but it is incremental as it extends deep learning to semi-competing risks with a hybrid statistical-ML approach.
The authors tackled the problem of predicting disease progression and mortality in lung cancer patients using semi-competing risk data, proposing a neural expectation-maximization algorithm that estimates baseline hazards, risk functions, and transition dependencies, and applied it to the Boston Lung Cancer Study to analyze clinical and genetic predictors.
Prognostication for lung cancer, a leading cause of mortality, remains a complex task, as it needs to quantify the associations of risk factors and health events spanning a patient's entire life. One challenge is that an individual's disease course involves non-terminal (e.g., disease progression) and terminal (e.g., death) events, which form semi-competing relationships. Our motivation comes from the Boston Lung Cancer Study, a large lung cancer survival cohort, which investigates how risk factors influence a patient's disease trajectory. Following developments in the prediction of time-to-event outcomes with neural networks, deep learning has become a focal area for the development of risk prediction methods in survival analysis. However, limited work has been done to predict multi-state or semi-competing risk outcomes, where a patient may experience adverse events such as disease progression prior to death. We propose a novel neural expectation-maximization algorithm to bridge the gap between classical statistical approaches and machine learning. Our algorithm enables estimation of the non-parametric baseline hazards of each state transition, risk functions of predictors, and the degree of dependence among different transitions, via a multi-task deep neural network with transition-specific sub-architectures. We apply our method to the Boston Lung Cancer Study and investigate the impact of clinical and genetic predictors on disease progression and mortality.